We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2008 by Peking University People's Hospital.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00630045
First Posted: March 6, 2008
Last Update Posted: March 6, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Peking University
Sanofi
Information provided by:
Peking University People's Hospital
  Purpose
This study aims to discuss the efficacy and safety of neoadjuvant chemotherapy with XELOX regimen (oxaliplatin plus capecitabine) .

Condition Intervention Phase
Colorectal Cancer Resectable Liver Metastasis Drug: neoadjuvant chemotherapy with oxaliplatin and capecitabine Procedure: resection of liver metastasis Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Study of Surgery in Combination With Neoadjuvant Chemotherapy of Oxaliplatin Plus Capecitabine in Colorectal Cancer With Respectable Liver Metastasis

Resource links provided by NLM:


Further study details as provided by Peking University People's Hospital:

Primary Outcome Measures:
  • disease free survival rate [ Time Frame: 3 year ]

Secondary Outcome Measures:
  • R0 resection rate [ Time Frame: at the time of pathological report ]
  • survival rate and over survival [ Time Frame: 5 year ]
  • surgery related mortality [ Time Frame: peri-operation period ]
  • response rate and safety of XELOX as a neoadjuvant regimen [ Time Frame: no time frame ]

Estimated Enrollment: 392
Study Start Date: January 2008
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
2~3 cycles of neoadjuvant chemotherapy before resection of liver metastasis
Drug: neoadjuvant chemotherapy with oxaliplatin and capecitabine
oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)
Procedure: resection of liver metastasis
surgery with the aim of R0 resection
Active Comparator: 2
no neoadjuvant chemotherapy, resect the liver metastasis directly
Procedure: resection of liver metastasis
surgery with the aim of R0 resection

Detailed Description:
Liver metastasis is the most important prognostic factor of colorectal cancer. Reasonable multidisciplinary therapy might improve the prognosis of patients with liver metastasis. Surgery has been the first choice under such situation. Recently, neoadjuvant chemotherapy has also shown its value in unresectable liver metastasis, for it can increase the chance of R0 resection and give some clues to chemosensitivity of agents. However, for those resectable lesions, the role and safety of neoadjuvant chemotherapy has yet to be confirmed. so we design this study.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed colorectal cancer with liver metastasis(all patients should have the pathological report of colorectal cancer. The chances of hepatocellular carcinoma or metastasis from other primary lesions should be excluded. )
  2. Liver metastasis should be resected with R0 resection and to save enough normal liver tissue
  3. Anticipated liver resection: for normal liver, ﹤70%; for liver with cirrhosis, ﹤50%
  4. No metastasis of other organs or lymph nodes in abdominal cavity
  5. No previous use of oxaliplatin and capecitabine, or previous adjuvant treatment ended more than 6 months
  6. Age 18 to 75 years old
  7. Karnofsky performance status ≥70
  8. Life expectancy of ≥3 month
  9. Bilirubin level < 1.5mg/dL
  10. Serum creatinine <1.0 times ULN
  11. Absolute neutrophil count ≥2000/mm3, platelet>100,000/mm3, Hb>9g/dl
  12. Having signed informed consent

Exclusion Criteria:

  1. previous use of oxaliplatin or fluorouracil-based chemotherapy in 6 months.
  2. No R0 resection or not enough normal liver tissue left
  3. previous radiotherapy of target lesions
  4. accompanied with unresectable other metastasis or malignant pleural fluids or ascites.
  5. complete or uncompleted liver obstruction
  6. peripheral neuropathy(NCI-CTC grade 1 or more)
  7. mental disturbance neuropathy that influence the cognition, including brain metastasis
  8. other serious disease such as uncontrollable active infection, heart infarction with 1 year, un controlled hypertension, arrhythmia with high risk, or unstable heart infarction,heart failure, coronary artery disease, myocardial infarction within the last 6 months
  9. Other previous malignancy within 5 year, except non-melanoma skin cancer
  10. accompany with other anti-tumor therapies,including immune therapy, intervention or injection with chemotherapeutical agents into serous cavity, or participating other clinical trials.
  11. Pregnancy or lactation period
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00630045


Contacts
Contact: zhou jing, MD 86-10-66583821 zhoujing58@sohu.com
Contact: Xiaotian Zhang, MD 86-10-88196561 zhangxt@yahoo.com

Locations
China, Beijing
Peking University, School of Oncology Recruiting
Beijing, Beijing, China, 100036
Contact: Xiaotian Zhang, MD    86-10-88196561    zhangxt@yahoo.com   
Contact: jifang gong, MD    86-10-88196088    goodjf@163.com   
China
Peking University, People's Hospital Recruiting
Beijing, China, 100044
Contact: jing zhou, MD    86-10-66583821    zhoujing58@sohu.com   
Sponsors and Collaborators
Peking University People's Hospital
Peking University
Sanofi
Investigators
Principal Investigator: Shan Wang, MD Peking University People's Hospital, Department of General Surgery
Principal Investigator: Lin Shen, MD Peking University, School of Oncology, Department of GI Oncology
  More Information

Responsible Party: Yeying Jiang/Associate professor, Peking University People's Hospital,Department of General Surgery
ClinicalTrials.gov Identifier: NCT00630045     History of Changes
Other Study ID Numbers: OXALIC
First Submitted: February 26, 2008
First Posted: March 6, 2008
Last Update Posted: March 6, 2008
Last Verified: February 2008

Additional relevant MeSH terms:
Colorectal Neoplasms
Neoplasm Metastasis
Liver Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes
Liver Diseases
Liver Extracts
Capecitabine
Oxaliplatin
Hematinics
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents